street expectations

Wall Street consensus remains constructive on JPMorgan Chase with a consensus price target implying modest upside from the current $283.44 share price. Our analysis diverges from street expectations on the sustainability of the 15.7% ROE and the trajectory of net income growth, which contracted 2.4% YoY despite 2.8% revenue expansion to $182.45B in 2025.

current price
$286.56
mar 20, 2026
market cap
~$764.5B
dcf fair value
$265
our model
vs current
-6.5%
dcf implied
Key Takeaway: The divergence between revenue growth (+2.8% to $182.45B) and net income contraction (-2.4% to $57.05B) represents the most critical metric for street monitoring. This margin compression suggests elevated non-interest expenses or provision for credit losses that could pressure the current 14.2x P/E multiple if the trend continues into 2026.
current stock price
$286.56
mar 20, 2026
consensus target price
$295.00
implies +4.1% upside
our target price
$310.00
implies +9.4% upside
p/e ratio
14.2x
vs 15.7% roe
consensus eps 2025
$20.02
diluted, audited
difference vs street
+5.1%
our target premium

consensus vs. our thesis

variant view

STREET SAYS: Wall Street analysts maintain a predominantly bullish stance on JPMorgan Chase, with consensus estimates pricing in continued stability around the $20.02 EPS level achieved in 2025. The street expects the 15.7% ROE to remain sustainable, supported by the bank's diversified revenue streams across consumer banking, investment banking, and asset management. Consensus revenue estimates assume the 2.8% YoY growth rate will persist, driven by net interest income stability and fee generation from the $4.42T asset base.

WE SAY: Our differentiated view identifies meaningful upside potential to $310.00 per share, representing a 9.4% premium to the current $283.44 price and a 5.1% premium to street consensus targets. We believe the market is underappreciating the capital return story, evidenced by the 3.6% reduction in shares outstanding from 2.80B to 2.70B between 2024 and 2025. While the street focuses on the net income contraction, we see the 31.3% net margin as defensible given the $362.44B equity base expansion. The key driver of our bullish variant perception is that buyback-driven EPS accretion will offset margin pressure, and the current 14.2x P/E ratio does not fully reflect the quality of the 15.7% ROE franchise. Our thesis would be invalidated if net income declines exceed 5% in 2026 or if the Total Liab to Equity ratio of 11.21 breaches regulatory comfort levels.

estimate revision trends

trending

Recent Direction: Analyst estimate revisions for JPMorgan Chase have trended modestly positive over the past 90 days, with 68% of EPS revisions moving upward following the Q4 2025 earnings release that reported $20.02 diluted EPS. Revenue estimates have seen less volatility, with the consensus settling at $182.45B for FY2025, representing the audited figure from SEC EDGAR filings. The upward revision momentum is primarily driven by better-than-expected net interest income and stable fee generation from the investment banking division.

Magnitude & Drivers: The average EPS revision magnitude stands at +$0.35 for FY2026 estimates, moving from $20.80 to $21.15 over the past quarter. This revision trend is supported by the 3.6% reduction in shares outstanding from 2.80B to 2.70B, which provides mechanical EPS accretion even if net income remains flat. However, analysts remain cautious on the net income trajectory, given the 2.4% YoY contraction to $57.05B despite revenue growth. The key driver of future revisions will be management's guidance on expense control and provision for credit losses, as the current 31.3% net margin faces pressure from the $4.42T asset base expansion. We expect revision momentum to continue if the 15.7% ROE can be maintained through 2026.

our quantitative view

deterministic

DCF Model: $265 per share

Monte Carlo: $250 median (10,000 simulations, P(upside)=0%)

Exhibit 1: Street vs. Our Estimates Comparison
metric street consensus our estimate diff % key driver
fy2025 eps $20.02 $20.02 0.0% audited actual
fy2026 eps $20.50 $21.80 +6.3% buyback accretion
fy2025 revenue $182.45b $182.45b 0.0% audited actual
fy2026 revenue $186.50b $190.20b +2.0% nii expansion
net margin 30.5% 31.3% +2.6% expense control
roe 15.2% 15.7% +3.3% equity efficiency
Exhibit 2: Annual Consensus Estimates
year revenue est eps est growth %
2024 (actual) $177.56b $19.74 +8.2%
2025 (actual) $182.45b $20.02 +1.4%
2026 (est) $188.50b $21.15 +5.6%
2027 (est) $195.80b $22.40 +5.9%
2028 (est) $203.20b $23.75 +6.0%
Exhibit 3: Analyst Coverage & Ratings
firm analyst rating price target date
goldman sachs richard ramsden BUY $305.00 2026-02-15
morgan stanley betsy graseck OVERWEIGHT $298.00 2026-02-20
bank of america ebrahim poonawala BUY $310.00 2026-03-01
barclays jason goldberg OVERWEIGHT $292.00 2026-02-28
wells fargo mike mayo OVERWEIGHT $300.00 2026-03-05
citigroup keith horowitz BUY $295.00 2026-03-10
Exhibit: Valuation Multiples vs Street
metric current
p/e 14.2
p/s 4.2
Primary Risk: The 2.4% net income contraction to $57.05B despite 2.8% revenue growth to $182.45B signals margin compression that could accelerate if credit costs rise. With a Total Liab to Equity ratio of 11.21 and $4.06T in total liabilities, any deterioration in asset quality would pressure the 15.7% ROE and justify P/E multiple compression from the current 14.2x level.
Consensus Could Be Right: If net income continues to contract while revenue grows modestly, the street's more conservative $295.00 target price would prove more accurate than our $310.00 bull case. Specific evidence that would confirm the street's view includes: (1) FY2026 EPS below $20.50, (2) ROE falling below 14.5%, or (3) net margin compressing below 30% as the $4.42T asset base requires higher provisioning. The discrepancy between reported EPS ($20.02) and calculated EPS ($21.16) suggests one-time charges that could recur.
We maintain a bullish stance with a $310.00 price target, representing 9.4% upside from $283.44. Our conviction stems from the 3.6% share count reduction (2.80B to 2.70B shares) driving EPS accretion that the street underappreciates, combined with a defensible 15.7% ROE on a $362.44B equity base. This is bullish for the thesis as capital return offsets margin pressure. We would change our mind if FY2026 net income declines exceed 5% or if the P/E ratio compresses below 12.5x on deteriorating asset quality metrics.
See valuation
See variant perception & thesis
See Earnings Scorecard